Evidence map›Paper›PMID 39093470›Full record

ArticleBulletin of experimental biology and medicine2024

Effects of the Pharmabiotic U-21 under Conditions of a Combined Neuroinflammatory Model of Parkinson's Disease in Rats.

A V Stavrovskaya, D N Voronkov, M V Marsova, A S Olshansky, A S Gushchina, V N Danilenko, S N Illarioshkin

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Gut Microbiome as a Source of Probiotic Drugs for Parkinson's Disease.International journal of molecular sciences · 2025
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

A V StavrovskayaResearch Center of Neurology, Moscow, Russia. alla_stav@mail.ru.
D N VoronkovResearch Center of Neurology, Moscow, Russia.
M V MarsovaVavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia.
A S OlshanskyResearch Center of Neurology, Moscow, Russia.
A S GushchinaResearch Center of Neurology, Moscow, Russia.
V N DanilenkoVavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia.
S N IllarioshkinResearch Center of Neurology, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Data on the participation of microbiota in the development of Parkinson's disease allow us to discuss the ability of bacterial preparations to influence the processes leading to neurodegeneration. We studied the effect of oral administration of Limosilactobacillus fermentum U-21 lyophilisate on a model of Parkinson's disease in rats induced by combined intranigral injection of LPS and systemic administration of paraquat. The toxins significantly increased the number of missteps in the "narrowing beam walking" test, but a tendency to a decrease in this parameter was shown after treatment with U-21. It should be noted that U-21 did not reduce the neuronal death in the substantia nigra, but mitigated the inflammatory glial response, decreased the accumulation of phosphorylated α-synuclein and complement protein C3. Our study demonstrated the efficiency of the combined model of parkinsonism and reduction of proinflammatory changes under the influence of pharmabiotic without changes in the nigral neuronal death and motor deficits.

Indexed as

alpha-SynucleinDisease Models, AnimalLipopolysaccharidesSubstantia NigraAnimalsComplement C3MaleNeuroinflammatory DiseasesParaquatParkinson DiseaseRatsRats, Wistaralpha-SynucleinComplement C3LipopolysaccharidesParaquatLimosilactobacillus fermentum U-21LPSparaquatParkinson’s diseasepharmabiotic

Identifiers

PMID39093470

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.